412 related articles for article (PubMed ID: 36875849)
41. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
[TBL] [Abstract][Full Text] [Related]
42. The role of the gut microbiota in NAFLD.
Leung C; Rivera L; Furness JB; Angus PW
Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
[TBL] [Abstract][Full Text] [Related]
43. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
Castelnuovo G; Perez-Diaz-Del-Campo N; Guariglia M; Poggiolini I; Armandi A; Rosso C; Caviglia GP; Bugianesi E
Minerva Gastroenterol (Torino); 2023 Mar; ():. PubMed ID: 36892817
[TBL] [Abstract][Full Text] [Related]
44. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
[TBL] [Abstract][Full Text] [Related]
45. Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men--the role of gut microbiota composition: study protocol for the AELC randomized controlled trial.
Liu WY; Lu DJ; Du XM; Sun JQ; Ge J; Wang RW; Wang R; Zou J; Xu C; Ren J; Wen XF; Liu Y; Cheng SM; Tan X; Pekkala S; Munukka E; Wiklund P; Chen YQ; Gu Q; Xia ZC; Liu JJ; Liu WB; Chen XB; Zhang YM; Li R; Borra RJ; Yao JX; Chen PJ; Cheng S
BMC Public Health; 2014 Jan; 14():48. PubMed ID: 24438438
[TBL] [Abstract][Full Text] [Related]
46. Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention.
Campagnoli LIM; Marchesi N; Vairetti M; Pascale A; Ferrigno A; Barbieri A
Cells; 2022 Sep; 11(18):. PubMed ID: 36139402
[TBL] [Abstract][Full Text] [Related]
47. Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice.
Xie F; Xu HF; Zhang J; Liu XN; Kou BX; Cai MY; Wu J; Dong JL; Meng QH; Wang Y; Chen D; Zhang Y
Front Immunol; 2022; 13():974872. PubMed ID: 36466835
[TBL] [Abstract][Full Text] [Related]
48. The Gut Microbiome and Ferroptosis in MAFLD.
Ji J; Wu L; Wei J; Wu J; Guo C
J Clin Transl Hepatol; 2023 Feb; 11(1):174-187. PubMed ID: 36406312
[TBL] [Abstract][Full Text] [Related]
49. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
Ji Y; Yin Y; Sun L; Zhang W
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
[TBL] [Abstract][Full Text] [Related]
50. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
51. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
[TBL] [Abstract][Full Text] [Related]
52. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
[TBL] [Abstract][Full Text] [Related]
53. Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): a study protocol of an efficacy mechanism evaluation.
Al-Awadi A; Grove J; Taylor M; Valdes A; Vijay A; Bawden S; Gowland P; Aithal G
BMJ Open; 2021 Oct; 11(10):e045802. PubMed ID: 34620653
[TBL] [Abstract][Full Text] [Related]
54. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.
Drożdż K; Nabrdalik K; Hajzler W; Kwiendacz H; Gumprecht J; Lip GYH
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010976
[TBL] [Abstract][Full Text] [Related]
55. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.
Hrncir T; Hrncirova L; Kverka M; Hromadka R; Machova V; Trckova E; Kostovcikova K; Kralickova P; Krejsek J; Tlaskalova-Hogenova H
Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946843
[TBL] [Abstract][Full Text] [Related]
56. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery.
Martínez-Montoro JI; Kuchay MS; Balaguer-Román A; Martínez-Sánchez MA; Frutos MD; Fernández-García JC; Ramos-Molina B
Obes Rev; 2022 Feb; 23(2):e13367. PubMed ID: 34729904
[TBL] [Abstract][Full Text] [Related]
57. Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease.
Delik A; Dinçer S; Ülger Y; Akkız H; Karaoğullarından Ü
Gene; 2022 Jul; 833():146587. PubMed ID: 35598686
[TBL] [Abstract][Full Text] [Related]
58. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).
Rong L; Zou J; Ran W; Qi X; Chen Y; Cui H; Guo J
Front Endocrinol (Lausanne); 2022; 13():1087260. PubMed ID: 36726464
[TBL] [Abstract][Full Text] [Related]
59. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
60. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
